ALK inhibitors in cancer:mechanisms of resistance and therapeutic management strategies  

作　　者：Darin Poei Sana Ali Shirley Ye Robert Hsu 

机构地区：[1]Department of Internal Medicine,University of Southern California,Los Angeles,CA 90033,USA [2]Division of Medical Oncology,University of Southern California Norris Comprehensive Cancer Center,Los Angeles,CA 90033,USA

出　　处：《Cancer Drug Resistance》2024年第1期690-711,共22页癌症耐药(英文)

摘　　要：Anaplastic lymphoma kinase(ALK)gene rearrangements have been identified as potent oncogenic drivers in several malignancies,including non-small cell lung cancer(NSCLC).The discovery of ALK inhibition using a tyrosine kinase inhibitor(TKI)has dramatically improved the outcomes of patients with ALK-mutated NSCLC.However,the emergence of intrinsic and acquired resistance inevitably occurs with ALK TKI use.This review describes the molecular mechanisms of ALK TKI resistance and discusses management strategies to overcome therapeutic resistance.

关 键 词：NSCLC ALK TKI acquired resistance alectinib CRIZOTINIB lorlatinib ceritinib brigatinib 

分 类 号：R73[医药卫生—肿瘤]